OPHTAI WAS INVOLVED IN A LARGE TELERETINAL SCREENING PROGRAM ORGANIZED BY UNIVERSITY OF WASHINGTON TO ASSESS DIABETIC RETINOPATHY ON 23,724 PATIENTS AT HOSPITALS IN SEATTLE AND ATLANTA
On January 7, 2021, Aaron Lee’s article in the ADA Diabetes Care was announcing OphtAI algorithms for automatic Diabetic Retinopathy assessment were the most sensitive ones on the market, and OphtAI was the only participant in the study providing better results than an ophthalmologist.
On January 11, 2021, Katyanna Quach elaborated on the study in the Register article available at the following link (https://www.theregister.com/2021/01/12/eye_doctor_ai/).
After interviewing Bruno Laÿ, OphtAI CTO, Katyanna wrote that Bruno believed research group’s conclusions were fair: “OphtAI’s algorithms were ranked as the best or second-best of the seven algorithms tested, and the technology from three out of the five companies trialed probably isn’t yet good enough to be used in the real world”. Katyanna also mentioned that the experiments were very challenging for all participants. Finally, Bruno told the reporter: “At the inception of the study, we had no idea of the quality of the images used in the test and moreover the clinical context was rather different from our regular use. We were able to process the whole dataset in just three days, and our system, which is CE marked, is already available for use in hospitals in France”.
Be part of this new trend based upon Artificial Intelligence applied to ophthalmology applications, contact OphtAI to learn more about this challenging technology and the way to use the most advanced and performing tools to automatically assess diabetic retinopathy, and other retinal pathologies.